Coreg Prices — US Pharmacy Cost vs Canada — Save Up to 96% in the US

Our most recent US pharmacy data shows a low of roughly $5.80 for Carvedilol with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.

Yes — Cost Plus Drugs lists Carvedilol at roughly $0.006 per unit, a published price with no membership card or coupon involved. See the three-price comparison above for how that stacks up against discount-card pharmacies.

We found Canadian pricing for Carvedilol starting near $0.150 per tablet in USD terms. That's before any shipping charge, which the table above breaks out separately.

Drug pricing is set separately in each country through different negotiation, regulatory, and distribution systems, so the same medication can legitimately carry different price tags on either side of the border. In this case, our data shows the US price is actually the lower of the two once a program like Cost Plus Drugs is factored in — the assumption that Canada is always cheaper doesn't hold for every drug.

Your out-of-pocket cost for Carvedilol with insurance depends entirely on your specific plan's formulary, deductible, and copay structure. To understand your exact cost, you should contact your insurance provider or ask your pharmacist. It can also be worthwhile to ask your pharmacist to compare your insurance copay against the price available through a prescription discount card, as the latter may sometimes offer a lower price.

Carvedilol is typically covered by Medicare Part D prescription drug plans. Your exact copay will vary based on your plan's phase of coverage (deductible, initial coverage, etc.). Because Medicare copays can fluctuate, some beneficiaries find that using a pharmacy savings card provides a more consistent and occasionally lower price than their standard Medicare cost-sharing.

Carvedilol is available as a generic medication produced by several pharmaceutical companies. The original branded versions are Coreg and its extended-release formulation, Coreg CR, which were developed by GlaxoSmithKline.